Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Source: SeekingAlpha
2026-04-29 10:29:58 ET
Regeneron Pharmaceuticals, Inc. ( REGN ) has just released its Q1 numbers .
So, its revenue rose 19.1% YoY to $3.61 billion , which came in well above the consensus estimate by $130 million. And yes, its non-GAAP EPS of $9.47 was also higher than what Wall Street analysts expected, as in the past 4 quarters , but this time by 57 cents....
Read the full article on Seeking Alpha
For further details see:
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
GSK plc American Depositary Shares (Each representing two)
NASDAQ: GSK
GSK Trading
1.21% G/L:
$52.37 Last:
2,698,925 Volume:
$51.91 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
